Close Menu

NEW YORK – Agilent Technologies said today that it has received CE-IVD marking in Europe for its PD-L1 IHC 22C3 assay for head and neck squamous cell carcinoma (HNSCC), a companion diagnostic in combination with Merck's anti-PD-1 immunotherapy pembrolizumab (Keytruda). 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.